$MRNA
Moderna, Inc.

2020 Q1 Form 10-Q Financial Statement

#000168285220000010 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $8.000M $16.03M
YoY Change -50.08% -44.82%
Cost Of Revenue $0.00
YoY Change
Gross Profit $8.000M
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $24.10M $27.30M
YoY Change -11.72% 67.48%
% of Gross Profit 301.25%
Research & Development $115.0M $130.4M
YoY Change -11.82% 44.7%
% of Gross Profit 1437.5%
Depreciation & Amortization $7.000M $7.300M
YoY Change -4.11% 40.38%
% of Gross Profit 87.5%
Operating Expenses $139.3M $157.7M
YoY Change -11.68% 48.13%
Operating Profit -$131.0M -$141.6M
YoY Change -7.51% 82.99%
Interest Expense $6.500M $9.400M
YoY Change -30.85% 80.77%
% of Operating Profit
Other Income/Expense, Net -$1.000M -$1.931M
YoY Change -48.21% 955.19%
Pretax Income -$124.0M -$132.6M
YoY Change -6.49% 83.21%
Income Tax $0.00 -$24.00K
% Of Pretax Income
Net Earnings -$124.0M -$132.6M
YoY Change -6.47% 83.18%
Net Earnings / Revenue -1550.0% -827.31%
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$0.35 -$403.3K
COMMON SHARES
Basic Shares Outstanding 353.0M shares 329.0M shares
Diluted Shares Outstanding 353.0M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.218B $1.109B
YoY Change 9.83%
Cash & Equivalents $392.0M $502.9M
Short-Term Investments $826.0M $606.0M
Other Short-Term Assets $13.00M $8.000M
YoY Change 62.5%
Inventory
Prepaid Expenses $12.41M $7.895M
Receivables $5.617M $8.948M
Other Receivables $12.00M $17.00M
Total Short-Term Assets $1.250B $1.141B
YoY Change 9.56%
LONG-TERM ASSETS
Property, Plant & Equipment $303.0M $209.5M
YoY Change 44.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $502.0M $438.0M
YoY Change 14.61%
Other Assets $1.736M $2.438M
YoY Change -28.79%
Total Long-Term Assets $817.6M $879.1M
YoY Change -7.0%
TOTAL ASSETS
Total Short-Term Assets $1.250B $1.141B
Total Long-Term Assets $817.6M $879.1M
Total Assets $2.068B $2.020B
YoY Change 2.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.03M $38.51M
YoY Change -71.35%
Accrued Expenses $55.02M $42.18M
YoY Change 30.43%
Deferred Revenue $58.84M $81.78M
YoY Change -28.04%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $134.6M $159.2M
YoY Change -15.44%
LONG-TERM LIABILITIES
Long-Term Debt $39.00M $33.00M
YoY Change 18.18%
Other Long-Term Liabilities $1.247M $213.0K
YoY Change 485.45%
Total Long-Term Liabilities $1.247M $213.0K
YoY Change 485.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $134.6M $159.2M
Total Long-Term Liabilities $1.247M $213.0K
Total Liabilities $426.7M $360.2M
YoY Change 18.46%
SHAREHOLDERS EQUITY
Retained Earnings -$1.620B -$982.4M
YoY Change 64.9%
Common Stock $37.00K $33.00K
YoY Change 12.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.641B $1.442B
YoY Change
Total Liabilities & Shareholders Equity $2.068B $2.020B
YoY Change 2.36%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$124.0M -$132.6M
YoY Change -6.47% 83.18%
Depreciation, Depletion And Amortization $7.000M $7.300M
YoY Change -4.11% 40.38%
Cash From Operating Activities -$106.0M -$144.3M
YoY Change -26.53% 29.52%
INVESTING ACTIVITIES
Capital Expenditures $6.000M $7.595M
YoY Change -21.0% -76.2%
Acquisitions
YoY Change
Other Investing Activities -$309.8M -$4.200M
YoY Change 7276.19% -99.07%
Cash From Investing Activities -$316.0M -$11.76M
YoY Change 2587.3% -97.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $550.0M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $578.0M $293.0K
YoY Change 197169.62% -99.95%
NET CHANGE
Cash From Operating Activities -$106.0M -$144.3M
Cash From Investing Activities -$316.0M -$11.76M
Cash From Financing Activities $578.0M $293.0K
Net Change In Cash $156.0M -$155.7M
YoY Change -200.17% 245.35%
FREE CASH FLOW
Cash From Operating Activities -$106.0M -$144.3M
Capital Expenditures $6.000M $7.595M
Free Cash Flow -$112.0M -$151.9M
YoY Change -26.25% 5.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001682852
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
336536985 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370102805 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
336536985 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370102805 shares
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
540000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1108000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93675000 USD
CY2020Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
38930000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
38689000 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1247000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
159987000 USD
CY2020Q1 mrna Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
202066000 USD
CY2019Q4 mrna Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
201495000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100533000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86414000 USD
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10791000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10791000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1736000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1931000 USD
CY2020Q1 us-gaap Assets
Assets
2067541000 USD
CY2019Q4 us-gaap Assets
Assets
1589422000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
11034000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7090000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55020000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67652000 USD
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
58842000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
63310000 USD
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9686000 USD
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
001-38753
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Moderna, Inc.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3467528
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Technology Square
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2020Q1 dei City Area Code
CityAreaCode
617
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
714-6500
CY2020Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2020Q1 dei Trading Symbol
TradingSymbol
MRNA
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
371223865 shares
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391720000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235876000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
825981000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
867124000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5617000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5032000 USD
CY2020Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
1683000 USD
CY2019Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
337000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23903000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19403000 USD
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1032000 USD
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1032000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
1249936000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1128804000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
502479000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
138000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
426667000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5063000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
134582000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
143115000 USD
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
142989000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
138995000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
108919000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
414612000 USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
37000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
34000 USD
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3267648000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2669426000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6127000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1804000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1620684000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1496454000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1640874000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1174810000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2067541000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1589422000 USD
CY2020Q1 us-gaap Revenues
Revenues
8389000 USD
CY2019Q1 us-gaap Revenues
Revenues
16025000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
115137000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
130413000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24114000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27253000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
139251000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
157666000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-130862000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-141641000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7852000 USD
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10972000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1154000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1931000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-124164000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-132600000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
66000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-124230000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-132576000 USD
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
353105021 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
328809986 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-124230000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-132576000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7610000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1908000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
321000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-3000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7931000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1911000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132161000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-130665000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1174810000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
549455000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28357000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20413000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7931000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-124230000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1640874000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1530241000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18497000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1911000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-132576000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1442325000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-124230000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-132576000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20413000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
18497000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7449000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7316000 USD
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-515000 USD
CY2019Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1005000 USD
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-137000 USD
CY2019Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-19000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
585000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6040000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
1346000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
66000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4305000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3354000 USD
CY2020Q1 mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
14119000 USD
CY2019Q1 mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
-1620000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2331000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1731000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-12953000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-32557000 USD
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-474000 USD
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15604000 USD
CY2020Q1 mrna Operating Lease Liabilities
OperatingLeaseLiabilities
15244000 USD
CY2019Q1 mrna Operating Lease Liabilities
OperatingLeaseLiabilities
-1848000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5732000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
811000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106191000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-144268000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
621257000 USD
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
429517000 USD
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
269733000 USD
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
403940000 USD
CY2020Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
41729000 USD
CY2019Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
21413000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6223000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7595000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-316018000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11759000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
549455000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
28357000 USD
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
57000 USD
CY2020Q1 mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
241000 USD
CY2019Q1 mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
236000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
578053000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
293000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
155844000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-155734000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247699000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
670491000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
403543000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
514757000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6610000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14127000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1620000000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
130413000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27253000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
157666000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-141641000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1931000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-132600000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-132576000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-132576000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7316000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3354000 USD
CY2019Q1 mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
-1620000 USD
CY2019Q1 mrna Operating Lease Liabilities
OperatingLeaseLiabilities
-1848000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
811000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-144268000 USD
CY2019Q1 mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
236000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
293000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391720000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
502934000 USD
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
1032000 USD
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10791000 USD
CY2019Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11823000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
403543000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
514757000 USD
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1972000 USD
CY2020Q1 mrna Contract With Customer Asset Increase During Period
ContractWithCustomerAssetIncreaseDuringPeriod
10718000 USD
CY2020Q1 mrna Contract With Customer Asset Decrease During Period
ContractWithCustomerAssetDecreaseDuringPeriod
9370000 USD
CY2020Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3320000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
199528000 USD
CY2020Q1 mrna Contract With Customer Liability Increase During Period
ContractWithCustomerLiabilityIncreaseDuringPeriod
7377000 USD
CY2020Q1 mrna Contract With Customer Liability Decrease During Period
ContractWithCustomerLiabilityDecreaseDuringPeriod
6304000 USD
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
6304000 USD
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
200601000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
85161000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
6835000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
724011000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
40000 USD
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1262000 USD
CY2020Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
278800000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
826449000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
825981000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
506983000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
502479000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1333432000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
1328460000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
7424000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
724011000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
7424000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
40000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
85161000 USD
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12410000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23903000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19403000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8475000 USD
CY2020Q1 mrna Tenant Incentives Receivables Current
TenantIncentivesReceivablesCurrent
3198000 USD
CY2019Q4 mrna Tenant Incentives Receivables Current
TenantIncentivesReceivablesCurrent
4093000 USD
CY2020Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
8295000 USD
CY2019Q4 mrna Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
201495000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7400000 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7300000 USD
CY2020Q1 mrna Property Plantand Equipmentand Finance Lease Rightof Use Assetbefore Accumulated Depreciationand Amortization
PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
303854000 USD
CY2019Q4 mrna Property Plantand Equipmentand Finance Lease Rightof Use Assetbefore Accumulated Depreciationand Amortization
PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetbeforeAccumulatedDepreciationandAmortization
296079000 USD
CY2020Q1 mrna Property Plantand Equipmentand Finance Lease Rightof Use Asset Accumulated Depreciationand Amortization
PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization
101788000 USD
CY2019Q4 mrna Property Plantand Equipmentand Finance Lease Rightof Use Asset Accumulated Depreciationand Amortization
PropertyPlantandEquipmentandFinanceLeaseRightofUseAssetAccumulatedDepreciationandAmortization
94584000 USD
CY2020Q1 mrna Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
202066000 USD
CY2020Q1 mrna Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
4350000 USD
CY2019Q4 mrna Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
4029000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12617000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27428000 USD
CY2020Q1 mrna Accrued External Goods And Services Current
AccruedExternalGoodsAndServicesCurrent
38053000 USD
CY2019Q4 mrna Accrued External Goods And Services Current
AccruedExternalGoodsAndServicesCurrent
36195000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55020000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67652000 USD
CY2019Q4 us-gaap Property Subject To Or Available For Operating Lease Number Of Units
PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits
2 campus
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100533000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86414000 USD
CY2020Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
9488000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
9544000 USD
CY2020Q1 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
110021000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3888000 USD
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3725000 USD
CY2020Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1425000 USD
CY2019Q4 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
95958000 USD
CY2019Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1387000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3987000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3584000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
108919000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93675000 USD
CY2020Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
38930000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
38689000 USD
CY2020Q1 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
147849000 USD
CY2019Q4 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
132364000 USD
CY2020Q1 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
151836000 USD
CY2019Q4 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
135948000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4636000 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3870000 USD
CY2020Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
73000 USD
CY2019Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
73000 USD
CY2020Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1665000 USD
CY2019Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1623000 USD
CY2020Q1 mrna Finance Lease Cost
FinanceLeaseCost
1738000 USD
CY2019Q1 mrna Finance Lease Cost
FinanceLeaseCost
1696000 USD
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1407000 USD
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
894000 USD
CY2020Q1 mrna Right Of Use Assets Reduced Through Lease Modifications And Reassessments
RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
0 USD
CY2019Q1 mrna Right Of Use Assets Reduced Through Lease Modifications And Reassessments
RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
219000 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16015000 USD
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17416000 USD
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
241000 USD
CY2019Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
236000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
10668000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
4313000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16266000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
5894000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16644000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
6054000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16962000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
6219000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
17380000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
6387000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
118015000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
264156000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
195935000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
293023000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
83018000 USD
CY2020Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
254093000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
112917000 USD
CY2020Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
38930000 USD
CY2020Q1 mrna Leases Imputed Interest Rate
LeasesImputedInterestRate
0.172
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
775000000 shares
CY2018Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
509352795 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
75000000.0 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
45536915 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2019Q4 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
7.35
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
286310000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3585069 shares
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
25.65
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.84
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3188671 shares
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.89
CY2020Q1 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
4.90
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
944715 shares
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.87
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.06
CY2020Q1 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
7.98
CY2020Q1 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue
9.68
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
44988598 shares
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
669827000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
22078150 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.04
CY2020Q1 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
5.42
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
417516000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
22910448 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.94
CY2020Q1 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
10.45
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
252311000 USD
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3200000 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
58000000.0 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28400000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20413000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18497000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20413000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18497000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
243400000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M8D
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-124230000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-132576000 USD
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
353105021 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
328809986 shares
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47050690 shares
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54433161 shares

Files In Submission

Name View Source Status
R1.htm Edgar Link pending
0001682852-20-000010-index-headers.html Edgar Link pending
0001682852-20-000010-index.html Edgar Link pending
0001682852-20-000010.txt Edgar Link pending
0001682852-20-000010-xbrl.zip Edgar Link pending
developmentpipeline.jpg Edgar Link pending
exhibit3113312020.htm Edgar Link pending
exhibit3123312020.htm Edgar Link pending
exhibit3213312020.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moderna10-q3312020.htm Edgar Link pending
moderna10-q3312020_htm.xml Edgar Link completed
modernacellmap.jpg Edgar Link pending
modernalogoa04.jpg Edgar Link pending
mrna-20200331.xsd Edgar Link pending
mrna-20200331_cal.xml Edgar Link unprocessable
mrna-20200331_def.xml Edgar Link unprocessable
mrna-20200331_lab.xml Edgar Link unprocessable
mrna-20200331_pre.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending